Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hLL1-DOX in NHL and CLL
NCT01585688Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Aug 2012
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of milatuzumab + doxorubicin in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Started Aug 2012; status: terminated.
02
Drugs
milatuzumab + doxorubicin
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01585688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01585688.